Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
Annals of Oncology, 06/26/09
Campo JMD et al. - Both every-3-weeks trabectedin regimes, 1.5 mg/m2 24 h and 1.3 mg/m2 3 h, were active and reasonably well tolerated in AOC platinum-sensitive patients. Trabectedin every-3-weeks has promising activity and deserves to be further evaluated in relapsed AOC.
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Drug dosage protocol for calcium oxalate stone
Urological Research - Urolithiasis, 10/23/09
Risperidone dose for schizophrenia
Cochrane Reviews, 10/21/09
Pediatric antifungal agents
Current Opinion in Infectious Diseases, 10/28/09
Sponsor
Article Search
Sponsor


See Latest Articles


